AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8545754 — intervention group
Group type: COMPARATOR
Intervention: RSCL (Rotterdam Symptom Checklist)
Number of subjects: 40
Study 8545754 — intervention group
Group type: COMPARATOR
Intervention: Spitzer QL‐Index
Number of subjects: 40
Study 2254507 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish language condition
Number of subjects: 80
Study 2254507 — intervention group
Group type: EXPERIMENTAL
Intervention: 2nd language condition (Spanish for English-Spanish bilinguals)
Number of subjects: 80
Study 2254507 — intervention group
Group type: EXPERIMENTAL
Intervention: mother tongue condition (Spanish for Spanish-English bilinguals)
Number of subjects: 80
Study 2254507 — intervention group
Group type: COMPARATOR
Intervention: Language usage (mother tongue vs 2nd language)
Number of subjects: 80
Study 7369252 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 30
Study 7369252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31085503 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 66
Study 31085503 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 66
Study 31115345 — intervention group
Group type: EXPERIMENTAL
Intervention: myCompass (Web-based CBT) for 8 weeks plus a 4-week tailing-off period
Number of subjects: 780
Study 31115345 — intervention group
Group type: COMPARATOR
Intervention: Active placebo intervention
Number of subjects: 780
Study 28853210 — intervention group
Group type: EXPERIMENTAL
Intervention: High Slowly Digestible Starch (HSDS) breakfast
Number of subjects: 20
Study 28853210 — intervention group
Group type: COMPARATOR
Intervention: Low Slowly Digestible Starch (LSDS) breakfast
Number of subjects: 20
Study 28853210 — intervention group
Group type: COMPARATOR
Intervention: Glucose solution (as a reference)
Number of subjects: 20
Study 28853210 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HSDS and LSDS products
Number of subjects: 20
Study 25641199 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl spray (INFS) 400 μg
Number of subjects: 46
Study 25641199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 24647500 — intervention group
Group type: EXPERIMENTAL
Intervention: 36mm metal-on-metal
Number of subjects: 105
Study 24647500 — intervention group
Group type: EXPERIMENTAL
Intervention: 28mm metal-on-metal
Number of subjects: 105
Study 24647500 — intervention group
Group type: COMPARATOR
Intervention: 28mm metal-on-polyethylene
Number of subjects: 105
Study 22116008 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment
Number of subjects: 0
Study 22116008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19406062 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Radial (LR) approach
Number of subjects: 1005
Study 19406062 — intervention group
Group type: COMPARATOR
Intervention: Femoral (F) approach
Number of subjects: 1005
Study 19406062 — intervention group
Group type: COMPARATOR
Intervention: Right Radial (RR) approach
Number of subjects: 1005
Study 19406062 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial approach (including LR and RR)
Number of subjects: 1005
Study 17330681 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg) plus methotrexate
Number of subjects: 76
Study 17330681 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate
Number of subjects: 76
Study 15501488 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 38
Study 15501488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 11929342 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg once daily for 7 days
Number of subjects: 401
Study 11929342 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin 500mg three times daily for 7 days
Number of subjects: 401
Study 9831572 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (n = 1215)
Number of subjects: 2440
Study 7498591 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer base material (Base Line, De Trey Dentsply)
Number of subjects: 0
Study 7498591 — intervention group
Group type: COMPARATOR
Intervention: Negative control group (reference materials: zinc phosphate cement and reference glass ionomer base material)
Number of subjects: 0
Study 30965392 — intervention group
Group type: EXPERIMENTAL
Intervention: Satavaptan (vasopressin V2 antagonist)
Number of subjects: 250
Study 30965392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 30965392 — intervention group
Group type: EXPERIMENTAL
Intervention: Satavaptan
Number of subjects: 250
Study 28648618 — intervention group
Group type: EXPERIMENTAL
Intervention: H-s.c. (subcutaneous trastuzumab)
Number of subjects: 113
Study 28648618 — intervention group
Group type: COMPARATOR
Intervention: H-i.v. (intravenous trastuzumab)
Number of subjects: 113
Study 28648618 — intervention group
Group type: EXPERIMENTAL
Intervention: H-s.c.
Number of subjects: 113
Study 28648618 — intervention group
Group type: COMPARATOR
Intervention: H-i.v.
Number of subjects: 113
Study 25892168 — intervention group
Group type: EXPERIMENTAL
Intervention: My Voice, My Choice (MVMC) program
Number of subjects: 83
Study 25892168 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 83
Study 24176198 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic, neuropathic group
Number of subjects: 23
Study 20195031 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine alkalinized to a pH of 7.09+/‐0.10 (Group B)
Number of subjects: 200
Study 20195031 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine at 37 degrees C alkalinized to a pH of 6.94+/‐0.05 (Group WB)
Number of subjects: 200
Study 20195031 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine at operating room temperature 18 degrees C (Group C)
Number of subjects: 200
Study 20195031 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine warmed to 37 degrees C (Group W)
Number of subjects: 200
Study 17644057 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy with rabeprazole 20mg o.d., levofloxacin 500 mg o.d., and amoxycillin 1g b.i.d. (4 tablets/day)
Number of subjects: 144
Study 17644057 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy comprising of rabeprazole 20mg, clarithromycin 500 mg, tinidazole 500 mg plus bovine lactoferrin 200mg (10 tablets/day)
Number of subjects: 144
Study 16372588 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI treatment for 4 weeks or more pre-operatively
Number of subjects: 80
Study 16372588 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ACEI treatment)
Number of subjects: 80
Study 12225725 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 5010
Study 12225725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5010
Study 10436103 — intervention group
Group type: EXPERIMENTAL
Intervention: Common carotid artery (CCA) diameter
Number of subjects: 104
Study 10436103 — intervention group
Group type: EXPERIMENTAL
Intervention: Common carotid artery (CCA) diameter in men
Number of subjects: 104
Study 10436103 — intervention group
Group type: EXPERIMENTAL
Intervention: Common carotid artery (CCA) diameter in women
Number of subjects: 104
Study 10436103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intima-media (IM) thickness
Number of subjects: 104
Study 7573844 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms
Number of subjects: 11
Study 7573844 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 200 micrograms
Number of subjects: 11
Study 7573844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 2130825 — intervention group
Group type: EXPERIMENTAL
Intervention: tablets containing Mg citrate/Mg lactate 5 mmol three times a day
Number of subjects: 18
Study 2130825 — intervention group
Group type: EXPERIMENTAL
Intervention: tablets containing Mg citrate/Mg lactate and Mg hydroxide, 5 mmol three times a day
Number of subjects: 18
Study 2130825 — intervention group
Group type: EXPERIMENTAL
Intervention: tablets containing Mg hydroxide (Emgesan 10.3 mmol) twice a day
Number of subjects: 18
Study 2130825 — intervention group
Group type: EXPERIMENTAL
Intervention: solutions with Mg chloride (0.5 mmol/ml) 10 ml three times a day
Number of subjects: 18
Study 2130825 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 7000224 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluids during or after operation (Wet)
Number of subjects: 60
Study 7000224 — intervention group
Group type: COMPARATOR
Intervention: No intravenous fluids (Dry)
Number of subjects: 60
Study 31117236 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernosal abobotulinumtoxinA (Dysport®) 250 or 500 U as add-on therapy
Number of subjects: 47
Study 31117236 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernosal abobotulinumtoxinA (Dysport®)
Number of subjects: 47
Study 28264080 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Pest Management (IPM) plus pest management education
Number of subjects: 361
Study 28264080 — intervention group
Group type: COMPARATOR
Intervention: Pest management education alone (Control)
Number of subjects: 361
Study 26545369 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week anti-inflammatory diet
Number of subjects: 20
Study 23974698 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation
Number of subjects: 29
Study 23974698 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 29
Study 21140269 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavanol-rich cocoa (918 mg)
Number of subjects: 18
Study 21140269 — intervention group
Group type: COMPARATOR
Intervention: Flavanol-poor cocoa
Number of subjects: 18
Study 20023338 — intervention group
Group type: EXPERIMENTAL
Intervention: Long segment instrumentation with fusion (WF)
Number of subjects: 42
Study 20023338 — intervention group
Group type: COMPARATOR
Intervention: Long segment instrumentation without fusion (WOF)
Number of subjects: 42
Study 20023338 — intervention group
Group type: COMPARATOR
Intervention: Both groups (WF and WOF)
Number of subjects: 42
Study 17016059 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam (7.5 mg cumulative dose)
Number of subjects: 21
Study 17016059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 15288981 — intervention group
Group type: EXPERIMENTAL
Intervention: Accommodating IOL (1CU)
Number of subjects: 55
Study 15288981 — intervention group
Group type: COMPARATOR
Intervention: Open-loop control IOL
Number of subjects: 55
Study 15288981 — intervention group
Group type: COMPARATOR
Intervention: Capsule polishing
Number of subjects: 55
Study 15288981 — intervention group
Group type: COMPARATOR
Intervention: Posterior capsulorhexis
Number of subjects: 55
Study 15288981 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 2%
Number of subjects: 55
Study 12206950 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated reaching/leaning task with foot support
Number of subjects: 12
Study 12206950 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated reaching/leaning task without foot support
Number of subjects: 12
Study 12206950 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement direction (forward)
Number of subjects: 12
Study 12206950 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement direction (backward)
Number of subjects: 12
Study 12206950 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement direction (lateral)
Number of subjects: 12
Study 9689507 — intervention group
Group type: EXPERIMENTAL
Intervention: New HF current generator with automatically controlled cut system (Endocut)
Number of subjects: 100
Study 9689507 — intervention group
Group type: COMPARATOR
Intervention: Conventional current generator
Number of subjects: 100
Study 7858768 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 64
Study 7858768 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 64
Study 2632753 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (0.5, 1.0, and 2.0 ng/kg per min)
Number of subjects: 19
Study 2632753 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose)
Number of subjects: 19
Study 2632753 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline (subthreshold doses)
Number of subjects: 19
Study 47280 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen 200 mg
Number of subjects: 0
Study 47280 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen 100 mg
Number of subjects: 0
Study 47280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 47280 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preferences
Number of subjects: 0
Study 30321318 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g force
Number of subjects: 15
Study 30321318 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 g force
Number of subjects: 15
Study 30321318 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 15
Study 27613906 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation (reflecting on personal values and positive traits using a questionnaire)
Number of subjects: 265
Study 27613906 — intervention group
Group type: COMPARATOR
Intervention: Matched control condition (no self-affirmation)
Number of subjects: 265
Study 26023212 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir monotherapy (arm A)
Number of subjects: 34
Study 26023212 — intervention group
Group type: COMPARATOR
Intervention: lopinavir/ritonavir+zidovudine/lamivudine tritherapy (arm B)
Number of subjects: 34
Study 24308770 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner presence
Number of subjects: 24
Study 24308770 — intervention group
Group type: COMPARATOR
Intervention: Partner absence
Number of subjects: 24
Study 22128296 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH (starting dose 50 IU for up to three treatment cycles)
Number of subjects: 302
Study 22128296 — intervention group
Group type: COMPARATOR
Intervention: CC (50‐150 mg/day for 5 days)
Number of subjects: 302
Study 19239405 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐to‐one pre‐ and postnatal breastfeeding education and support from a lactation consultant
Number of subjects: 104
Study 19239405 — intervention group
Group type: COMPARATOR
Intervention: Standard breastfeeding services (Control)
Number of subjects: 104
Study 17897270 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (inspired concentrations varying from 2% to 5%)
Number of subjects: 33
Study 17897270 — intervention group
Group type: COMPARATOR
Intervention: No medication (preoxygenation with 100% oxygen alone)
Number of subjects: 33
Study 16305601 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurologist consultation
Number of subjects: 38
Study 16305601 — intervention group
Group type: COMPARATOR
Intervention: Community care physicians (CCPs)
Number of subjects: 38
Study 11912385 — intervention group
Group type: EXPERIMENTAL
Intervention: Abarelix depot 100 mg
Number of subjects: 255
Study 11912385 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide acetate 7.5 mg plus bicalutamide 50 mg daily
Number of subjects: 255
Study 10217442 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Signal Classification (MUSIC)
Number of subjects: 0
Study 10217442 — intervention group
Group type: COMPARATOR
Intervention: Principal Component Analysis (PCA)
Number of subjects: 0
Study 7815657 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic version of scenarios (2 options)
Number of subjects: 680
Study 7815657 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded version of scenarios (3 options)
Number of subjects: 680
Study 2128988 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy plus adjuvant ovariectomy
Number of subjects: 34
Study 2128988 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy only
Number of subjects: 34
Study 573763 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-limited therapy
Number of subjects: 42
Study 573763 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-unlimited therapy
Number of subjects: 42
Study 573763 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 573763 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-limited and open-ended therapy (follow-up)
Number of subjects: 42
Study 31891407 — intervention group
Group type: EXPERIMENTAL
Intervention: Tart cherry juice concentrate (7.5 ml, 15 ml, 22.5 ml, or 30 ml twice daily for 28 days)
Number of subjects: 50
Study 31891407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 29235560 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk (1.5 g fat/100 mL)
Number of subjects: 60
Study 29235560 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened soft drinks (SSSD)
Number of subjects: 60
Study 29235560 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-caloric soft drink (NCSD)
Number of subjects: 60
Study 29235560 — intervention group
Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 60
Study 27686642 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (0.1 mg/kg)
Number of subjects: 60
Study 27686642 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (0.001 mg/kg)
Number of subjects: 60
Study 27686642 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezocine (0.1 mg/kg)
Number of subjects: 60
Study 25424209 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaper cream applied twice daily (group II)
Number of subjects: 89
Study 25424209 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet wipes and diaper cream applied twice daily (group III)
Number of subjects: 89
Study 25424209 — intervention group
Group type: COMPARATOR
Intervention: Water-moistened washcloths at diaper changes (group I)
Number of subjects: 89
Study 22561463 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor led training
Number of subjects: 214
Study 22561463 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited instructor with manikin feedback
Number of subjects: 214
Study 22561463 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed learning
Number of subjects: 214
Study 21029013 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (intra-arterial, endothelium-dependent vasodilator)
Number of subjects: 115
Study 21029013 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (intra-arterial, endothelium-independent vasodilator)
Number of subjects: 115
Study 18418454 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanida 500mg every 12 hours for 3 days
Number of subjects: 120
Study 18418454 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 12 hours for 3 days
Number of subjects: 120
Study 15812303 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar patients
Number of subjects: 32
Study 15812303 — intervention group
Group type: COMPARATOR
Intervention: Healthy male controls
Number of subjects: 32
Study 12431929 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal Teaching Associate (RTA)
Number of subjects: 65
Study 12431929 — intervention group
Group type: COMPARATOR
Intervention: Lecture and simulated model
Number of subjects: 65
Study 10499136 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention course designed to promote physical activity
Number of subjects: 338
Study 8734175 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsynchronized burst pacing
Number of subjects: 38
Study 8734175 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized burst pacing
Number of subjects: 38
Study 8734175 — intervention group
Group type: COMPARATOR
Intervention: Ramp pacing
Number of subjects: 38
Study 8734175 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal pacing
Number of subjects: 38
Study 1661762 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II/isoprenaline
Number of subjects: 10
Study 1661762 — intervention group
Group type: COMPARATOR
Intervention: Isoprenaline
Number of subjects: 10
Study 1661762 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II
Number of subjects: 10
Study 1661762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7161138 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets containing 70.0 mg ascorbic acid, 2.0 mg riboflavin, and 2.0 mg pyridoxine
Number of subjects: 0
Study 7161138 — intervention group
Group type: COMPARATOR
Intervention: Untreated control groups
Number of subjects: 0
Study 30584120 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure release
Number of subjects: 60
Study 30584120 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonophoresis with betamethasone
Number of subjects: 60
Study 30584120 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 60
Study 28379325 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training + Caloric Restriction (RT+CR)
Number of subjects: 123
Study 28379325 — intervention group
Group type: COMPARATOR
Intervention: Aerobic Training + Caloric Restriction (AT+CR)
Number of subjects: 123
Study 25915628 — intervention group
Group type: EXPERIMENTAL
Intervention: FRF treatment at 67 °C for 3 seconds
Number of subjects: 0
Study 25915628 — intervention group
Group type: EXPERIMENTAL
Intervention: FRF treatment at 62 °C
Number of subjects: 0
Study 25915628 — intervention group
Group type: EXPERIMENTAL
Intervention: FRF treatment at 52 °C-57 °C
Number of subjects: 0
Study 25915628 — intervention group
Group type: EXPERIMENTAL
Intervention: FRF treatment at 62 °C to 67 °C
Number of subjects: 0
Study 25531046 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept 6 mg/kg plus docetaxel 75 mg/m²
Number of subjects: 20
Study 25531046 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept 4 mg/kg plus docetaxel 75 mg/m²
Number of subjects: 20
Study 22262486 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin and IV ferric gluconate
Number of subjects: 187
Study 22262486 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin and oral ferrous sulfate
Number of subjects: 187
Study 22262486 — intervention group
Group type: COMPARATOR
Intervention: Epoetin and no iron
Number of subjects: 187
Study 19927684 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct instruction
Number of subjects: 66
Study 19927684 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback
Number of subjects: 66
Study 19927684 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated exposure
Number of subjects: 66